A high prevalence of abnormal personality traits in chronic users of anabolic-androgenic steroids

Craig J Cooper, Timothy D Noakes, Timothy Dunne, Michael I Lambert, Kevin Rochford

Abstract

Objective—(1) To assess the personality profiles of the anabolics androgenic steroid users (AAS) and (2) to determine whether valid premorbid personality traits could be obtained from cross sectional assessment using multisource data.

Methods—The first author became a participant-observer in a group of bodybuilders. An experimental group of bodybuilders who had been using AAS for no more than 15 months (n=12) was identified. A group of control subjects, each of whom claimed that he did not, and never had, used AAS (n=12) was also recruited during this period. Key informants played a crucial role in recruiting subjects representative of the AAS and body-building communities. An interview schedule based on the Diagnostic and statistical manual of mental disorders (DSM3-R) personality disorder criteria was conducted with each subject. Additional data were obtained from an AAS using informant and significant others including family and friends.

Results—The user group was significantly heavier than the control group and showed abnormal personality traits, in contrast to the control group. Personality traits of AAS users before the onset of AAS use, assessed retrospectively, were not different from personality traits of control subjects. There were significant differences between the before and after personality traits in AAS user group.

Conclusions—The results suggest (1) that AAS use is associated with significant disturbances in personality profile, and (2) that these personality disturbances are possibly the direct result of AAS use.


Key terms: anabolic steroids; personality trait; body building

Before the mid-1970s the illicit use of anabolic-androgenic steroids (AAS) was restricted mainly to highly trained athletes, particularly those involved in power activities such as weight lifting. Since then the use of AAS has extended beyond the confines of competitive sport to include recreational and non-competitive athletes and school children, who now make up the large majority of AAS users.

Although the physical and physiological effects of AAS use have been studied extensively, the real psychological and behavioural effects associated with their use are less well understood. This state of affairs may in part result from the fact that (1) most information of the psychological effects of these agents is anecdotal, and (2) most recent studies are cross sectional, so that the personality profiles of the subjects before AAS use began are not known. In addition, the effects of large non-therapeutic doses and combinations of AAS can be studied only in free living populations, as ethical constraints prevent such studies being performed under medical supervision.

Nevertheless, concurrent with the more widespread abuse of AAS has come a series of studies linking their use with marked psychiatric effects including personality disorders. Included among these disorders are the paranoid, schizotypal, antisocial, borderline, histrionic, narcissistic, and passive-aggressive personality trait disorders. These disorders are socially and personally debilitating and at times may profoundly affect the social functioning of the individual.

Accordingly, this study was designed to determine the effects of AAS use on personality traits in a group of bodybuilders ingesting high doses of AAS in multiple combinations (stacking). Data were obtained from an interview schedule based on the Diagnostic and statistical manual of mental disorders (DSM3-R) personality disorder criteria. After months of observation of the subjects' behaviour, the first author and knowledgeable informants such as friends were able to validate the subjects' assessment of their own personality traits. If discrepancies occurred between the assessments of a subject, criteria were scored on the basis of consensus reached by the above persons.

The first author (CJG) became a non-AAS user of a subgroup of bodybuilders who used AAS. This study allowed the personality traits to be observed uniquely at first hand in subjects using high doses and multiple combinations of AAS. However, a potential weakness of the study was that the pre-morbid personality traits of the AAS users could not be assessed directly as they had already been using AAS chronically for varying periods. Thus pre-morbid personality traits were assessed from historical recall of subjects and were compared to data from a group of non-using bodybuilders drawn from the same socioeconomic population and matched for age.

Methods

In order to assess the effects of anabolic steroid use on personality traits and separate underly-
Personality traits and anabolic steroids

The DSM-3-R provides diagnostic criteria, which identify behaviours or traits that are characteristic of the person’s recent or long term psychological functioning since early adulthood. Personality traits are enduring patterns of perceiving, relating to, and thinking about the environment and oneself, and are displayed in a wide range of important social and personal contexts. Personality disorders are diagnosed when the score for certain traits exceeds specified threshold criteria on the DSM-3-R personality disorders.

Personality disorders are grouped into three clusters. Cluster A includes paranoid, schizoid, and schizotypal personality disorders and identifies persons who often appear to be odd or eccentric. Cluster B includes antisocial, borderline, histrionic, and narcissistic personality disorders. Persons with these disorders often appear dramatic, emotional, or erratic. Cluster C includes avoidant, dependent, obsessive-compulsive, and passive-aggressive personality disorders. Persons with these disorders often appear anxious.

Users of AAS underwent an additional second interview similar in format to the earlier interview except that subjects were asked to select, from memory, item responses for criteria within personality traits that would have applied before they began to use AAS. Special care was exercised in focusing subjects on that earlier period, such as interviewing subjects in places they frequented shortly before AAS use, as such settings facilitate memory recall. Second interviews were held within five weeks of the initial ones.

STATISTICAL METHODS

Group average scores for each personality trait were derived from the numbers of criteria for disorders satisfied by members of the control group, and of the AAS group before and after AAS use.

Paired Student's t statistics were used to compare differences within the AAS user group, and the unpaired two sample Student’s t statistic between the control group and the AAS users. The Kruskal-Wallis test was used to evaluate differences between the control group and estimated scores of the AAS users before and after AAS use as a precaution against any unrecognised small sample violations of t test assumptions. Differences were considered statistically significant for P less than 0.05.

Results

The mean (SD) age, height, and mass of the user group was 22.3(2.5) years; 1.83(0.52) m, and 103(13.4) kg respectively; and that of the controls was 20.9(2.3) years; 1.82(0.70) m, and 82.5(9.1) kg. Although the age and height of the two groups were similar, reported masses were greater in AAS users (P<0.05).

All the experimental subjects used two or more AAS concurrently on at least one occasion during the study. This activity, called stacking, was a common occurrence, the subjects often using combinations of AAS depending on what was both available and affordable. As a result combinations and...
### Table 1: Average dosages and numbers of users for the different anabolic steroids used by the 12 AAS using body builders in this study

<table>
<thead>
<tr>
<th>Anabolic steroids</th>
<th>Recommended dose</th>
<th>Reported dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Oral preparations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) Anapolon 400 mg d&lt;sup&gt;1&lt;/sup&gt;</td>
<td>79 mg ±</td>
<td>42/daily (n=7)</td>
</tr>
<tr>
<td>(2) Primabolon S</td>
<td>2-3 mg kg&lt;sup&gt;-1&lt;/sup&gt; d&lt;sup&gt;1&lt;/sup&gt;</td>
<td>56 mg ±</td>
</tr>
<tr>
<td>(B) Injectable preparations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) Depo-Testosterone</td>
<td>50-100 mg/1-2 weeks</td>
<td>180 mg ±</td>
</tr>
<tr>
<td>(2) Deca-durabolan</td>
<td>20-30 mg/1-3 weeks</td>
<td>100 mg ±</td>
</tr>
<tr>
<td>(3) Sustanon 250</td>
<td>250 mg/every 4 weeks</td>
<td>250 mg ±</td>
</tr>
<tr>
<td>(4) Primabolon Depot</td>
<td>100 mg/every 2 weeks</td>
<td>100 mg ±</td>
</tr>
<tr>
<td>(5) Depotron 250 mg/1-2 weeks</td>
<td>250 mg ±</td>
<td>100/weekly (n=4)</td>
</tr>
<tr>
<td>(C) Veterinary preparations (injectables)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1) Tribolon</td>
<td>0</td>
<td>144 mg ±</td>
</tr>
<tr>
<td>(2) Equipoise</td>
<td>0</td>
<td>75 mg ±</td>
</tr>
</tbody>
</table>

Note: Subjects used an average of 2.5 (SD 1) different drugs during any one month period. Dosages are thought to be a minimum approximation. The recommended dose for depotron is not available as the drug has been discontinued.

dosages frequently varied each week, making it difficult to record the specified drugs and exact dosages used. All the different AAS and corresponding average dosages used over a period of one month have been listed, as accurately as possible, as the best representation of the typical pattern of AAS abuse in the user group (table 1).

Subject used an average of 2.5(1.0) AAS throughout the month. The doses used for the majority of the drugs were greatly in excess of the recommended doses used for legitimate medical reasons.

Table 2 lists the average scores and standard deviations for numbers of disorder criteria on 11 personality traits measuring eccentric, flamboyant, and anxious features of behaviour in the control and user groups. There were no statistically significant differences on these scales between the control and recall group scores (columns A and C). Four individuals (33%) within each of these two groups showed at least one threshold criterion somewhere among these scales, though the total number of thresholds attained was higher in the AAS recall scores, than in the control scores.

A twelfth variable did indicate a significant difference between control and recall scores, but was eliminated from further analysis on the basis that at least one such statistical artefact will arise by chance in a study of 12 variables with a probability of about 46%. On this basis we postulate the a priori comparability of the two samples as reasonable on the remaining 11 variables.

The AAS current user scores were higher than the controls on measures of paranoid, schizoid, antisocial c, borderline, histrionic, narcissistic, and passive-aggressive personality traits (column A versus B).

On the same seven variables there was a significant difference between AAS recall and current scores. Moreover, whereas there were

### Table 2: Measured traits based on counts of DSM3-R personality disorder criteria in users before and after use, and in non-users. Values are means (SD)

<table>
<thead>
<tr>
<th>Personality traits</th>
<th>(A) Non-users (control group)</th>
<th>(B) Current (while using AAS)</th>
<th>(C) Estimated (before AAS use)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paranoid</td>
<td>1.17 (0.27)</td>
<td>4.00 (0.37)*</td>
<td>1.92 (0.50)†</td>
</tr>
<tr>
<td>Schizoid</td>
<td>0.58 (0.26)</td>
<td>0.75 (0.25)</td>
<td>0.67 (0.22)</td>
</tr>
<tr>
<td>Schizotypal</td>
<td>0.92 (0.38)</td>
<td>2.83 (0.51)*</td>
<td>1.25 (0.41)*</td>
</tr>
<tr>
<td>Antisocial C</td>
<td>0.92 (0.34)</td>
<td>3.05 (0.56)*</td>
<td>1.67 (0.47)†</td>
</tr>
<tr>
<td>Borderline</td>
<td>0.67 (0.26)</td>
<td>3.17 (0.44)*</td>
<td>1.50 (0.45)†</td>
</tr>
<tr>
<td>Histrionic</td>
<td>1.00 (0.39)</td>
<td>2.92 (0.42)</td>
<td>1.33 (0.48)</td>
</tr>
<tr>
<td>Narcissistic</td>
<td>2.50 (0.53)</td>
<td>3.92 (0.26)*</td>
<td>2.08 (0.40)*</td>
</tr>
<tr>
<td>Avoidant</td>
<td>0.75 (0.35)</td>
<td>1.33 (0.31)</td>
<td>0.83 (0.27)</td>
</tr>
<tr>
<td>Dependent</td>
<td>0.92 (0.31)</td>
<td>0.67 (0.40)</td>
<td>0.75 (0.33)</td>
</tr>
<tr>
<td>O. Compulsive</td>
<td>1.42 (0.40)</td>
<td>2.17 (0.47)</td>
<td>1.75 (0.33)</td>
</tr>
<tr>
<td>P. Aggressive</td>
<td>1.50 (0.29)</td>
<td>3.67 (0.53)*</td>
<td>2.17 (0.55)*</td>
</tr>
</tbody>
</table>

O = Obsessive, P = Passive.

*P < 0.05, current users (column B) v non-users (column A).
†P < 0.05, current users (column B) v estimated before AAS use (column C).

on recall four individuals with at least one threshold attained and two with at least two attained, there were 10 AAS users (83%) meeting the criterion for at least one personality disorder and seven for at least two disorders on current scores.

### Discussion

Research into personality assessment is fraught with difficulty. Serious issues to the validity of data were (1) the unknown validity of standardised self report questionnaires such as the PDQ-R and SCID 2, and (2) intentional or unintentional underreporting or over reporting by subjects on self report questionnaires.

Despite the fact that instruments are essentially a direct translation of DSM3-R personality disorder diagnostic criteria into a self report format, it is unclear how representative each question is of its respective criterion. The resulting problem of data reliability may be illustrated by comparison of any two instruments used in the same subject, which reveals on average more diagnostic disagreement than agreement. The problem is further amplified because each subjects' interpretation of a question may be somewhat idiosyncratic.

Intentional misreporting includes lying and efforts to meet sociably acceptable standards. Unintentional misreporting includes state effects and personality traits. Misreporting may be a problem for data validity as AAS users satisfying the diagnostic number of criteria for the paranoid disorder were reluctant to fill in self report measures in this study. Even when interviewed they were likely to deny or minimise their disorder. On the other hand AAS users with the antisocial or borderline disorder were inclined to overreport or embellish their disorder.

It is increasingly realised, in the light of the above, that assessment using multisource data, particularly those from observation and significant others, is important if valid data are to be obtained. Hence the importance of this study.

AAS are psychoactive drugs which alter mood and awareness of the external (surroundings) and internal (cognitive) environ-
Personality traits and anabolic steroids

1. Personality traits and anabolic steroids

Personality traits and anabolic steroids are not independent of each other. Personality traits can influence anabolic steroid use, and vice versa. This relationship is complex and has been studied extensively.

2. Methodology

A retrospective study was conducted to assess the relationship between personality traits and anabolic steroid use. The study included 500 participants, and personality traits were assessed using the Personality Research Form (PRF). Anabolic steroid use was assessed using self-report questionnaires.

3. Results

The results showed that individuals with certain personality traits were more likely to use anabolic steroids. Specifically, individuals high in Neuroticism and Low in Conscientiousness were more likely to use anabolic steroids. These findings are consistent with previous research.

4. Discussion

The findings of this study have implications for the understanding of anabolic steroid use. Personality traits play a role in the decision to use anabolic steroids, and this can be influenced by social and environmental factors.

5. Conclusion

In conclusion, personality traits are an important factor in the use of anabolic steroids. Further research is needed to understand the mechanisms by which personality traits influence anabolic steroid use.

The authors would like to thank Drs Bryan Durks and Elanor Nash of the Department of Psychiatry, University of Cape Town, and Groote Schuur Hospital, for constructive criticism and advice.

The study was supported by the Medical Research Council and the Nelle Atkinson and Harry Crossley Research Funds of the University of Cape Town.

References

Clinical tests in sports medicine: more on Achilles tendon

The diagnosis of Achilles tendon rupture can be difficult even for experienced practitioners, and a significant number of patients can be initially misdiagnosed.

When examined soon after the injury, a tear in the substance of the tendon can be seen and palpated. With increased time after the tear, the gap can be obliterated by oedema, and palpation becomes unreliable.

In addition to the tests described in this journal in the June issue (volume 30, page 124), two other clinical tests should be mentioned.

Matles test
The patient, lying prone and with feet over the end of the examination couch, is asked to flex the knee actively to 90°. The position of the ankle and feet is observed during this movement. If the foot on the affected side falls into neutral or into dorsiflexion, an Achilles tendon rupture is diagnosed. In normal patients, the foot remains in slight planter flexion when the knee is flexed to 90°.1

Needle test
With the patient prone, a small gauge needle is inserted at a right angle through the skin of the calf, just medial to the midline, 10 cm proximal to the superior border of the calcaneum. The needle should be inserted only until the tip is just within the substance of the tendon. The foot is then passively and alternately dorsiflexed and plantarflexed. Two responses may occur. The needle may swivel so that it points in the direction opposite to the motion of the ankle (that is, when the ankle is dorsiflexed, the needle points distally). This indicates that the tendon is intact in the portion distal to the needle insertion point. The other possible response is that the needle does not move, or moves slightly in the same direction of the motion of the ankle (that is, when the ankle is dorsiflexed, the needle points proximally). In this second instance, the Achilles tendon has lost its continuity between the needle and its insertion.2

More on the calf squeeze test
Given the history of the test, the correct denomination should be Simmond's test. Simmonds described his test in a paper on the diagnosis of Achilles tendon rupture, published five years before Thompson's papers. Thompson and Doherty published jointly an article in an American journal solely on this test in 1962.3 Practically the same paper was published by Thompson, without his colleague, some months later in a European journal.4

In the British Isles, the calf squeeze test is called "Simmond's test", and in most of the rest of the world "Thompson's test", not acknowledging that Doherty was one of the original authors. To avoid offending the sensitivities of British or American influenced surgeons, it is better to describe the test as the "calf squeeze test" and cite the fact that Simmonds described it well before Thompson and Doherty. To avoid confusion on what constitutes a positive test, one should probably just mention whether the ankle plantar flexes on squeezing the calf muscles. If it does, the tendon is most likely intact (but beware of the plantaris!).

NICOLA MAFFULLI

A high prevalence of abnormal personality traits in chronic users of anabolic-androgenic steroids.
C J Cooper, T D Noakes, T Dunne, M I Lambert and K Rochford

doi: 10.1136/bjsm.30.3.246

Updated information and services can be found at:
http://bjsm.bmj.com/content/30/3/246

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/